Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Sequential therapy of abiraterone and enzalutamide in castration-resistant prostate cancer: a systematic review and meta-analysis

K. Mori, N. Miura, H. Mostafaei, F. Quhal, R. Sari Motlagh, B. Pradere, S. Kimura, T. Kimura, S. Egawa, A. Briganti, PI. Karakiewicz, SF. Shariat

. 2020 ; 23 (4) : 539-548. [pub] 20200309

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, metaanalýza, systematický přehled

Perzistentní odkaz   https://www.medvik.cz/link/bmc21026400
E-zdroje Online Plný text

NLK ProQuest Central od 2000-07-01 do Před 1 rokem
Open Access Digital Library od 1997-01-01
Health & Medicine (ProQuest) od 2000-07-01 do Před 1 rokem
Public Health Database (ProQuest) od 2000-07-01 do Před 1 rokem

Odkazy

PubMed 32152435
DOI 10.1038/s41391-020-0222-6
Knihovny.cz E-zdroje

BACKGROUND: This systematic review and meta-analysis aimed to assess the prognostic value of sequential of abiraterone (ABI) and enzalutamide (ENZ) therapy in patients with castration-resistant prostate cancer (CRPC). METHODS: PUBMED, Web of Science, Cochrane Library, and Scopus databases were searched for articles published prior to December 2019 according to the Preferred Reporting Items for Systematic Review and Meta-analysis statement. Studies were deemed eligible if they compared overall survival (OS), combined progression-free survival (PFS), combined prostate specific antigen (PSA)-PFS, and PSA response rates in CRPC patients receiving sequential ABI/ENZ or vice versa. PSA response to both the first and second agents was defined as a >50% decrease in PSA achieved with each of these agents. Formal meta-analyses were performed for these outcomes. RESULTS: Ten studies with 1096 patients were eligible for the systematic review and eight studies with 643 patients for the meta-analysis. The ABI-to-ENZ sequence was significantly associated with better PFS (pooled hazard ratio (HR): 0.62, 95% confidential interval (CI): 0.49-0.78, P < 0.001), and PSA-PFS (pooled HR: 0.48, 95% CI: 0.38-0.61, P < 0.001) than the ENZ-to-ABI sequence. PSA response rates of both agents were significantly better with the ABI-to-ENZ sequence (risk ratio: 0.21, 95% CI: 0.09-0.47, P < 0.001). In contrast, treatment sequence was not significantly associated with OS (pooled HR: 0.77, 95% CI: 0.59-1.01, P = 0.055). CONCLUSIONS: ABI-to-ENZ sequential therapy in patients with CRPC was associated with better PFS, PSA-PFS, and PSA response rates. Regardless of sequencing, response to drug therapy was transient for both ABI and ENZ when either agent was used as a secondary therapy. Despite this, treatment sequencing is important to achieve the maximum possible benefit from available drugs in CRPC.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026400
003      
CZ-PrNML
005      
20211026132933.0
007      
ta
008      
211013s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41391-020-0222-6 $2 doi
035    __
$a (PubMed)32152435
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Mori, Keiichiro $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
245    10
$a Sequential therapy of abiraterone and enzalutamide in castration-resistant prostate cancer: a systematic review and meta-analysis / $c K. Mori, N. Miura, H. Mostafaei, F. Quhal, R. Sari Motlagh, B. Pradere, S. Kimura, T. Kimura, S. Egawa, A. Briganti, PI. Karakiewicz, SF. Shariat
520    9_
$a BACKGROUND: This systematic review and meta-analysis aimed to assess the prognostic value of sequential of abiraterone (ABI) and enzalutamide (ENZ) therapy in patients with castration-resistant prostate cancer (CRPC). METHODS: PUBMED, Web of Science, Cochrane Library, and Scopus databases were searched for articles published prior to December 2019 according to the Preferred Reporting Items for Systematic Review and Meta-analysis statement. Studies were deemed eligible if they compared overall survival (OS), combined progression-free survival (PFS), combined prostate specific antigen (PSA)-PFS, and PSA response rates in CRPC patients receiving sequential ABI/ENZ or vice versa. PSA response to both the first and second agents was defined as a >50% decrease in PSA achieved with each of these agents. Formal meta-analyses were performed for these outcomes. RESULTS: Ten studies with 1096 patients were eligible for the systematic review and eight studies with 643 patients for the meta-analysis. The ABI-to-ENZ sequence was significantly associated with better PFS (pooled hazard ratio (HR): 0.62, 95% confidential interval (CI): 0.49-0.78, P < 0.001), and PSA-PFS (pooled HR: 0.48, 95% CI: 0.38-0.61, P < 0.001) than the ENZ-to-ABI sequence. PSA response rates of both agents were significantly better with the ABI-to-ENZ sequence (risk ratio: 0.21, 95% CI: 0.09-0.47, P < 0.001). In contrast, treatment sequence was not significantly associated with OS (pooled HR: 0.77, 95% CI: 0.59-1.01, P = 0.055). CONCLUSIONS: ABI-to-ENZ sequential therapy in patients with CRPC was associated with better PFS, PSA-PFS, and PSA response rates. Regardless of sequencing, response to drug therapy was transient for both ABI and ENZ when either agent was used as a secondary therapy. Despite this, treatment sequencing is important to achieve the maximum possible benefit from available drugs in CRPC.
650    _2
$a antagonisté androgenů $x aplikace a dávkování $7 D000726
650    _2
$a androsteny $x aplikace a dávkování $7 D000736
650    _2
$a benzamidy $x aplikace a dávkování $7 D001549
650    _2
$a klinické zkoušky, fáze II jako téma $7 D017322
650    _2
$a progrese nemoci $7 D018450
650    _2
$a rozvrh dávkování léků $7 D004334
650    _2
$a lidé $7 D006801
650    _2
$a kalikreiny $x krev $7 D007610
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a nitrily $x aplikace a dávkování $7 D009570
650    _2
$a fenylthiohydantoin $x aplikace a dávkování $7 D010669
650    _2
$a prostatický specifický antigen $x krev $7 D017430
650    _2
$a nádory prostaty rezistentní na kastraci $x krev $x farmakoterapie $x patologie $7 D064129
650    _2
$a randomizované kontrolované studie jako téma $7 D016032
650    _2
$a míra přežití $7 D015996
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a metaanalýza $7 D017418
655    _2
$a systematický přehled $7 D000078182
700    1_
$a Miura, Noriyoshi $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Department of Urology, Ehime University Graduate School of Medicine, Ehime, Japan
700    1_
$a Mostafaei, Hadi $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Research Center for Evidence Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
700    1_
$a Quhal, Fahad $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Department of Urology, King Fahad Specialist Hospital, Dammam, Saudi Arabia
700    1_
$a Sari Motlagh, Reza $u Department of Urology, Medical University of Vienna, Vienna, Austria
700    1_
$a Pradere, Benjamin $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Department of Urology, CHRU Tours, Francois Rabelais University, Tours, France
700    1_
$a Kimura, Shoji $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
700    1_
$a Kimura, Takahiro $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
700    1_
$a Egawa, Shin $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
700    1_
$a Briganti, Alberto $u Division of Oncology, Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy
700    1_
$a Karakiewicz, Pierre I $u Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, QC, Canada
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Medical University of Vienna, Vienna, Austria. shahrokh.shariat@meduniwien.ac.at $u Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia. shahrokh.shariat@meduniwien.ac.at $u Department of Urology, Weill Cornell Medical College, New York, NY, USA. shahrokh.shariat@meduniwien.ac.at $u Department of Urology, University of Texas Southwestern, Dallas, TX, USA. shahrokh.shariat@meduniwien.ac.at $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. shahrokh.shariat@meduniwien.ac.at $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. shahrokh.shariat@meduniwien.ac.at $u Department of Urology, University of Jordan, Amman, Jordan. shahrokh.shariat@meduniwien.ac.at $u European Association of Urology Research Foundation, Arnhem, Netherlands. shahrokh.shariat@meduniwien.ac.at
773    0_
$w MED00008064 $t Prostate cancer and prostatic diseases $x 1476-5608 $g Roč. 23, č. 4 (2020), s. 539-548
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32152435 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026132939 $b ABA008
999    __
$a ok $b bmc $g 1715192 $s 1146907
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 23 $c 4 $d 539-548 $e 20200309 $i 1476-5608 $m Prostate cancer and prostatic diseases $n Prostate Cancer Prostatic Dis $x MED00008064
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Možnosti archivace